Lineage Cell Therapeutics Inc (LCTX) — Capital Reinvestment Ratio

Latest as of March 2022: 0.00x

Lineage Cell Therapeutics Inc (LCTX) has a Capital Reinvestment Ratio of 0.00x as of March 2022, meaning it reinvests 0% of its operating cash flow ($21.90 Million) in capital expenditures ($46.00K). See Lineage Cell Therapeutics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.00x

Capex / Operating Cash Flow

Operating Cash Flow

$21.90 Million

USD

Capital Expenditures

$46.00K

USD

Data as of

Mar 2022

Most recent filing

Lineage Cell Therapeutics Inc Capital Reinvestment Ratio (2022–2022)

This chart tracks Lineage Cell Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods.

Annual Capital Reinvestment Ratio for Lineage Cell Therapeutics Inc (2022–2022)

Year-by-year Capital Reinvestment Ratio for Lineage Cell Therapeutics Inc from 2022 to 2022. For live market cap and broader valuation context, see Lineage Cell Therapeutics Inc (LCTX) total market value.

Year	Reinvestment Ratio	Operating CF (USD)	Capital Expenditures	YoY Change
2022	0.39x	$1.06 Million	$413.00K	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow